Examiner: KANE, TREVOR LOGAN

Tech Center 1700 • Art Units: 1651 1657 1699 1791

This examiner grants 69% of resolved cases

Analysis

Trevor Logan Kane works in Tech Center 1700 and Art Unit 1651, where he has handled 110 resolved cases. The data reveals an allowance rate pct of 69.1 and a median days to allowance of 1230. These 110 resolved cases establish a pattern of outcomes for applications in Art Unit 1651. The 69.1 percent allowance rate indicates the frequency of successful grants.

The interview lift pct of 52.4 shows that personal engagement provides a substantial increase in the probability of allowance. This 52.4 percent lift suggests that interviews are an exceptionally effective tool for resolving issues. Practitioners can use the 1230 days to allowance to plan for the duration of the prosecution. The 69.1 percent allowance rate and 1230 days to allowance are the key indicators for this examiner. The 110 resolved cases provide the basis for these observations.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

69.4%

Allow Rate

+4.4% vs TC avg

143

Total Applications

+52.5%

Interview Lift

1229

Avg Prosecution Days

Based on 111 resolved cases, 2023–2026

Rejection Statute Breakdown

6.4%

§101 Eligibility

15.8%

§102 Novelty

42.0%

§103 Obviousness

29.5%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
18579156	NOVEL BETA-CAROTENE 15,15-OXYGENASE VARIANT AND RETINOID PRODUCTION METHOD USING SAME	Non-Final OA	CJ CHEILJEDANG CORPORATION
17931704	COMPOSITIONS AND METHODS FOR TREATING CELIAC SPRUE DISEASE	Non-Final OA	The Regents of the University of California
18300014	ANASTASIS BIOSENSOR	Non-Final OA	THE JOHNS HOPKINS UNIVERSITY
17913503	COMPOSITIONS AND METHODS FOR DIABETES TREATMENT	Final Rejection	The General Hospital Corporation
17738799	METHODS FOR ENGINEERING THERAPEUTICS AND USES THEREOF	Final Rejection	The Trustees of Columbia University In The City of New York
18110934	ENGINEERED PROTEIN DELIVERY PLATFORM AND USE THEREOF FOR ANTIBACTERIAL TREATMENTS	Final Rejection	RAMOT AT TEL AVIV UNIVERSITY LTD.
18039514	MODIFICATION OF SAPONINS	Non-Final OA	GLAXOSMITHKLINE BIOLOGICALS SA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy